Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes.


Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia… (More)

1 Figure or Table


  • Presentations referencing similar topics